Trial reportClinical and vaccine immunology : CVI2017
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8
Open access · diamondAbstract readClinical Trial, Phase IRandomized Controlled Trial
In one paragraph
Trial report in Clinical and vaccine immunology : CVI, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119.JCI insight · 2024Trial
- Trial
- Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines.Communications biology · 2020Trial
- DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial.The Journal of clinical investigation · 2019Trial
- Trial
- High-Dimensional Multimodal Data Integration for Immune-Driven Diseases: A Practical Guide.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- Advances in host-directed therapy for tuberculosis and HIV coinfection: enhancing immune responses.Trends in microbiology · 2025Review
- Benchmarking single-cell cross-omics imputation methods for surface protein expression.Genome biology · 2025Article
- An integrated single-cell atlas of blood immune cells in aging.npj aging · 2024Article
- Article
- Orthogonal multimodality integration and clustering in single-cell data.BMC bioinformatics · 2024Article
- STREAK: A supervised cell surface receptor abundance estimation strategy for single cell RNA-sequencing data using feature selection and thresholded gene set scoring.PLoS computational biology · 2023Article
- IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines.Frontiers in immunology · 2022Review
- Induction of food-specific IgG by Gene Gun-delivered DNA vaccines.Frontiers in allergy · 2022Article
- Article
- A multiple T cell epitope comprising DNA vaccine boosts the protective efficacy of Bacillus Calmette-Guérin (BCG) against Mycobacterium tuberculosis.BMC infectious diseases · 2020Article
- Nucleic Acid-Based Approaches for Tumor Therapy.Cells · 2020Review
- Immune effect of a Newcastle disease virus DNA vaccine with IL-12 as a molecular adjuvant delivered by electroporation.Archives of virology · 2020Article
- Nucleic acid-based therapy for coronavirus disease 2019.Heliyon · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 11 institutions in 1 country.
Shuying S LiVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Nidhi K KocharVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Marnie ElizagaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Christine M HayInfectious Diseases Division, University of Rochester Medical Center, Rochester, New York, USA.
Gregory J WilsonDivision of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Kristen W CohenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Stephen C De RosaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Rong XuProfectus BioSciences, Tarrytown, New York, USA.
Ayuko Ota-SetlikProfectus BioSciences, Tarrytown, New York, USA.
Daryl MorrisVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Greg FinakVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Mary AllenNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Hong-Van TieuLaboratory of Infectious Disease Prevention, New York Blood Center, New York, New York, USA.
Ian FrankDepartment of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Magdalena E SobieszczykDivision of Infectious Diseases, Columbia University Medical Center, New York, New York, USA.
Drew HannamanIchor Medical Systems, Inc., San Diego, California, USA.
Raphael GottardoVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Peter B GilbertVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Lawrence CoreyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
David K ClarkeProfectus BioSciences, Tarrytown, New York, USA.
Michael A EganProfectus BioSciences, Tarrytown, New York, USA.
John H EldridgeProfectus BioSciences, Tarrytown, New York, USA.
M Juliana McElrathVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Nicole FrahmVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA nfrahm@fredhutch.org.ORCID http://orcid.org/0000-0003-1298-3676
NIAID HIV Vaccine Trials Network
Fred Hutch Cancer Center · USProfectus Biosciences (United States) · USUniversity of Washington · USColumbia University Irving Medical Center · USDuke Medical Center · USIchor Medical Systems (United States) · USNational Institutes of Health · USNew York Blood Center · USUniversity of Pennsylvania · USUniversity of Rochester Medical Center · USVanderbilt University Medical Center · US
Funding
LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6MLC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6MSDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9MVirus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DAVID S METZGER · 1999 to 2026
$78.6MColumbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8MVanderbilt HIV Clinical Trials Unit (CTU)UM1AI069439 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David W Haas, Spyros A Kalams · 2012 to 2026
$33.1MUniversity of Pennsylvania HIV Clinical Trials UnitUM1AI069534 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ian Frank, PABLO TEBAS · 2012 to 2026
$33.0MUniversity of Rochester HIV/AIDS Clinical Trials Unit Administrative SupplementUM1AI069511 · NIAID · UNIVERSITY OF ROCHESTER · PI Paul R Bohjanen, MICHAEL C KEEFER · 2012 to 2026
$25.7MColumbia Collaborative HIV/AIDS Clinical Trials UnitU01AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HAMMER, SCOTT M · 2007 to 2011
$15.4MUnits for HIV/AIDS Clinical Trials NetworksU01AI069511 · NIAID · UNIVERSITY OF ROCHESTER · PI KEEFER, MICHAEL C · 2007 to 2011
$12.0MFHCRC High-Performance Computing ClusterS10OD020069 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KOOPERBERG, CHARLES L · 2015 to 2015
$600kNIAID NIH HHS P30 AI045008NIAID NIH HHS U01 AI069470NIAID NIH HHS U01 AI069511NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI069439NIAID NIH HHS UM1 AI069470NIAID NIH HHS UM1 AI069511NIAID NIH HHS UM1 AI069534NIH HHS S10 OD020069
Abstract
The HIV Vaccine Trials Network (HVTN) 087 vaccine trial assessed the effect of increasing doses of pIL-12 (interleukin-12 delivered as plasmid DNA) adjuvant on the immunogenicity of an HIV-1 multiantigen (MAG) DNA vaccine delivered by electroporation and boosted with a vaccine comprising an attenuated vesicular stomatitis virus expressing HIV-1 Gag (VSV-Gag). We randomized 100 healthy adults to receive placebo or 3 mg HIV-MAG DNA vaccine (ProfectusVax HIV-1
Indexed as
Immunogenicity, VaccineAdjuvants, ImmunologicAdultAIDS VaccinesCD8-Positive T-LymphocytesEpitope MappingFemalegag Gene Products, Human Immunodeficiency VirusGenetic VectorsHIV-1HIV InfectionsHumansImmunization, SecondaryInterleukin-12MaleMiddle AgedAdjuvants, ImmunologicAIDS Vaccinesgag Gene Products, Human Immunodeficiency VirusInterleukin-12Vaccines, DNADNA primeHIVIL-12T cellvaccineVSV vector
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.